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  14 
Abstract 15 
Reasons for performing study: Recommendations for prophylactic vaccination against 16 
tetanus in horses vary greatly between countries and have scarce scientific support in the 17 
peer-reviewed literature. In human medicine, recommended booster vaccination intervals 18 
are also very variable, but are considerably longer than for horses. More information is 19 
needed about the duration of immunity induced by modern vaccines. 20 
Objectives: To investigate if the duration of antibody titres previously determined to be 21 
protective against tetanus differ from what is indicated by recommended vaccination 22 
intervals for horses. 23 
Study design: Prospective seroconversion study. 24 
Methods: Thirty-four horses were enrolled for basic immunisation with an ISCOM Matrix-25 
combination vaccine (Equilis® Prequenza Te). Horses received the first vaccination at 5-11 26 
months of age, and the second dose 4 weeks later. A third vaccine dose was given 15-17 27 
months after the second dose. Serum tetanus antibody titres were analysed by ToBi ELISA 2 28 
weeks as well as 14-16 months after the second dose. After the third vaccine dose, titres were 29 
checked once yearly for 3 years. Results were described by age and level of antibody titre at 30 
first sampling. 31 
Results: Two weeks after the second dose all horses (34/34) had antibody levels that 32 
exceeded the limit of detection, 0.04 IU/ml. After 16 months the levels were above 0.04 IU/ml 33 
in 28/33 horses, the remaining 5 horses potentially had suboptimal protection against 34 
tetanus. After the third vaccine dose antibody levels remained above 0.04 IU/ml in 25/26 35 
horses for 1 year, 16/16 horses for 2 years, and 8/8 horses for 3 years. 36 
Conclusions: Horses that undergo basic immunisation with 3 doses of vaccine after the age of 37 
5 months are likely to have serum antibody titres consistent with protection against tetanus 38 
for more than 3 years. Current guidelines for tetanus prophylaxis should be revised.  39 
Introduction 40 
Tetanus prophylaxis is part of routine veterinary care for horses in the industrialised world, 41 
but recommendations for best practice vary widely between countries. For example, the 42 
AAEP guidelines recommend annual boosters after basic immunisation, but state that 43 
protective titres may persist for longer [1]. In Sweden, the general recommendation for 44 
practitioners is to give a tetanus vaccination booster once every 3 years, whereas in the UK it 45 
is generally recommended to give the booster every 2 years. In New Zealand, tetanus vaccines 46 
are registered for boosters at 5-year intervals after basic immunisation 47 
(http://www.ivsonline.co.nz). The situation is similar in human practice, where the 48 
recommended booster intervals after basic immunisation vary between countries. However, 49 
all intervals are considerably longer than postulated for horses with at least 10-20 years 50 
between boosters being the norm.  51 
Horses are one of the more susceptible species to tetanus based on relative amount of toxin 52 
per weight required to produce lethal disease [2]. This is coupled with the fact that horses 53 
may often be exposed to environments containing spores of C. tetani, increasing the risk of 54 
contamination of wounds. These factors warrant good prophylaxis, however, more evidence-55 
based knowledge is needed on the duration of immunity. Previous studies have examined 56 
long-term duration of titres [3-9], and these consistently show that what is thought to be 57 
protective titres (>0.01 IU/ml) are well maintained for several years, but the vaccines used in 58 
these studies often contain adjuvants that are no longer in use such as water in oil emulsions, 59 
and results may not be able to be extrapolated to vaccines currently available.  60 
The aim of this 3-year longitudinal study was to determine the development and duration of 61 
tetanus antibody titres after basic immunisation of horses, using a combined tetanus and 62 
influenza vaccine1 with ISCOM matrix. 63 
Material and Methods 64 
Horses 65 
Thirty-four privately owned horses were enrolled at the start of the study. Horses were 66 
identified through convenience sampling; owners known to the researchers were approached 67 
and offered to participate based on likely availability for follow-up for the length of the study 68 
period. Horses were eligible if they were between 5 and 11 months of age, had not previously 69 
been vaccinated and were in good health as reported by the owners.  Horses were managed 70 
and housed according to the owners’ routine at 6 different facilities. In addition to the study 71 
protocol the horses were only vaccinated against influenza, according to the owners´ 72 
management procedures. Once enrolled, exclusion criteria were tetanus vaccination for other 73 
reasons than the study (for example at the treating veterinarian’s discretion if the horse 74 
sustained a wound) or steroid treatment. Owners could remove horses from the study at any 75 
point should they wish to do so.  76 
Vaccine 77 
The vaccine consisted of an aqueous suspension of purified haemagglutinin and 78 
neuraminidase proteins of equine influenza virus together with 40 Lf/dose of tetanus toxoid. 79 
Each dose of 1 ml contained 375 μg ISCOM matrix as adjuvant.  80 
Vaccination and sampling 81 
Horses received the first vaccination with Equilis® Prequenza Te1 at the start of the study and 82 
the second dose 4 weeks later. A third vaccine dose was given 15-17 months after the second 83 
dose. This protocol was based on the recommendations for basic immunization against 84 
tetanus with the used vaccine. Serum samples were obtained by jugular venepuncture prior 85 
to the first vaccination, 2 weeks after the second vaccination, 14-16 months after the second 86 
vaccination and once yearly for 3 years after the third vaccination (Figure 1). The blood was 87 
centrifuged on site after sampling, and serum was frozen as soon as possible prior to 88 
transportation to a -80°C freezer. Samples were kept at  89 
-80°C until the time of analysis (1-2 years) and samples were analysed consecutively on 3 90 
separate occasions throughout the study. 91 
Samples were transported to the laboratory on dry ice, ensuring that the samples were kept  92 
frozen until analysis.  93 
Analysis 94 
Antibody levels were determined by tetanus toxin-binding ELISA (ToBi ELISA) as previously 95 
described [8]. Twofold serial dilution of serum samples were made in a microtiter plate. After 96 
addition of a fixed dose of tetanus toxoid, the plates were incubated. During incubation the 97 
neutralizing tetanus antibodies in the serum are bound to the toxoid. The following day, the 98 
content of the plates was transferred to a novel microtiter plate coated with tetanus toxoid 99 
specific antibodies to determine the amount of non-neutralized (unbound) tetanus toxoid still 100 
remaining in the serum sample. Biotinylated tetanus specific antibodies and avidin-101 
peroxidase were used to visualize the captured tetanus toxoid in an ELISA, thereafter the 102 
antibody titres in the samples were calculated. The WHO International Standard for tetanus 103 
antitoxin was used as a standard in each test. The limit of detection was 0.04 IU/ml. 104 
  105 
Data analysis 106 
The non-normally distributed antibody titre levels, at each time point, were described as 107 
medians and interquartile range (IQR).  Categorical variables were described as counts and 108 
percentages. Where appropriate, variables were stratified by age, sex and breed. An outcome 109 
variable of detectable titre level at the start of the study (<0.04 IU/ml) was created as a binary 110 
variable (0=<0.04 IU/ml, 1=>0.04 IU/ml).  The Wilcoxon Mann Whitney test was used to 111 
compare the outcome of detectable titre level and the median age of horses at the start of 112 
the study and the titre level of horses at time points 1, 2, 3, 4 and 5. Median and IQR antibody 113 
levels were represented graphically, stratified by detectable titre level at the start of the study 114 
(Figure 2).  Other than for the categorical outcome of detectable titre level, antibody levels 115 
below the detectable limit were excluded from the statistical analyses.  All analyses were 116 
conducted using Stata version 11.  117 
 118 
Results 119 
Titres were obtained for 34 horses after the first vaccination but numbers declined 120 
throughout the study for reasons unrelated to this project and 8 horses (24%) remained at 121 
the end of the experimental study period (Table 1). Titres for individual horses are provided 122 
as supplementary material.  Horses received their first vaccination (V1) at a median age of 7 123 
months (IQR 6 to 8 months). Age at the start of the study was missing for one horse.  124 
At the first serum sampling, 13 horses (38%) had antibody levels below the limit of detection 125 
(<0,04 IU/ml). Horses with no detectable antibodies had a median age of 7.5 months (IQR 6 126 
to 8 months), compared to horses with detectable antibody levels with a median age of 6 127 
months (IQR 6 to 7 months; P<0.02). Two weeks after the second vaccine dose (V2) horses 128 
with no detectable antibodies at time point 0 had a median titre of 8.23 IU/ml (IQR 4.61 to 129 
13.98 IU/ml), compared to a titre of 2.16 IU/ml (IQR 1.10 to 4.73 IU/ml; P<0.01) for horses 130 
that did have detectable antibodies at time point 0 (Figure 2). There was no significant 131 
difference between horses with detectable and no detectable antibodies at time point 2 132 
(P<0.25), time point 3 (P<0.17), time point 4 (P<0.08) or time point 5 (P<0.12).  133 
Two weeks after the second dose, all 34 horses had antibody levels that exceeded 0.04 IU/ml. 134 
After 16 months the levels were above 0.04 IU/ml in 28/33 horses (85%). After the third 135 
vaccine dose antibody levels remained above 0.04 IU/ml in 25/26 horses (96%) for 1 year, all 136 
16/16 horses for 2 years, and all 8/8 horses for 3 years. 137 
 138 
Discussion 139 
This study suggests that horses that undergo basic immunisation with 3 doses of tetanus 140 
vaccine after the age of 5 months are likely to have serum antibody titres consistent with 141 
protection against tetanus for more than 3 years. Long term studies of adult horses have 142 
shown that most horses have titres above 0.01 IU/ml for 5-8 years after basic immunisation 143 
[3,4,9]. However, adult horses likely mount a stronger immune response than horses < 1 year 144 
old [7]. Also, horses that have undergone previous immunisations may not be comparable to 145 
naïve, not previously vaccinated individuals. The minimum IgG titre level for protection of 146 
horses has been set to 0.01 IU/ml. This is likely a direct extrapolation from the human 147 
recommendations for protective titres, which in turn are based on studies in guinea pigs 148 
[5,10-12], and is to the best of the authors’ knowledge not based on experimental evidence 149 
that a slightly lower titre would put horses at risk of disease after intoxication. In fact, in one 150 
study a horse with a serum IgG level as low as 0.0025 IU/ml failed to develop signs of tetanus 151 
after subcutaneous injection of 3 times the lethal dose of tetanus toxin [3]. The ToBi ELISA 152 
used in this study is comparable to the mouse inoculation test [13] and was chosen for ethical 153 
and animal welfare reasons in order to decrease the use of lab animals. Unfortunately the 154 
limit of detection for this method of analysis was 0.04 IU/ml, which is above the suggested 155 
limit for protection. Therefore, the horses that were below the limit of detection may or may 156 
not have been above the least accepted IgG level of 0.01 IU/ml.  In the present study, 13 157 
horses had IgG titres below 0.04 IU/ml before the first vaccination. Horses developed a strong 158 
antibody response after the two initial vaccinations despite the presence of maternal 159 
antibodies, confirming results from a previous study [9]. Within 2 weeks all horses had high 160 
titres (Figure 2), but horses with maternal antibodies present had a significantly lower 161 
response than horses with no detectable antibodies at the start of the study, indicating that 162 
the maternal antibodies may interfere with the immune response to tetanus vaccination. 163 
Maternal antibodies have previously been suggested to interfere with the response to tetanus 164 
vaccination [7], but that study may have been biased by the young age of the foals (3 months) 165 
as Jansen and Knoetze (1979) have shown that foals less than 3 months of age are unable to 166 
respond to vaccination, even in the absence of maternal tetanus antibodies. The fact that all 167 
horses had high antibody titres 2 weeks after the second dose of vaccine suggests that 168 
elective surgical procedures could safely be done at this time. Fourteen to 16 months after 169 
the two basic immunisations, 5/33 (15%) horses had antibody titres below 0.04 IU/ml. As it 170 
was unknown if these horses were below the proposed limit of protection, a third vaccination 171 
was included in the immunisation protocol.  172 
Recommendations for tetanus vaccination boosters vary widely between different countries. 173 
It is not always possible to find the scientific basis for these recommendations but some 174 
hypotheses can be made. The AAEP guidelines from 1995 [1] state that protective titres may 175 
be attained for up to 5 years, but recommend yearly boosters for all horses and additional 176 
vaccination if a horse sustains a wound more than 6 months after the last booster. This is 177 
supported by a case series [14] where the prognosis for survival was better if horses had been 178 
vaccinated within one year. However, when looking more closely at this data only 4/20 horses 179 
in this data set were known to be vaccinated. Three of these 4 horses survived. It is not 180 
specified how many doses of vaccine these horses had been given, however, judging by the 181 
age of the horses and the information given, only one of the vaccinated horses could have 182 
received 3 tetanus vaccinations as  a basic immunisation (in this text further referred to as 183 
“complete basic immunisation”). The Swedish recommendation of a 3 year booster interval 184 
was merely “decided” in 1991 at the time of product registration for one of the tetanus 185 
vaccines in the country (Agneta Gustafsson, pers com 2014). There is one recent study [8] 186 
showing that 7/7 horses had tetanus IgG titres above 0.04 IU/ml for two years after complete 187 
basic immunisation with Equilis Prequenza Te, indicating that yearly boosters are excessive. 188 
The New Zealand recommendation of a 5-yearly booster interval may be based on a paper by 189 
Liefman (1980) where the author recommends this booster interval in the discussion. 190 
Unfortunately, enquiries to the pharmaceutical companies responsible for these products in 191 
New Zealand have failed to yield information to confirm this. Comparison between 192 
immunisation studies is complicated by the use of different vaccines and adjuvants which may 193 
have some impact, especially when comparing more recent work to older experiments. Also, 194 
the early toxicity studies use different modes of inoculation (subcutaneous vs intramuscular 195 
vs inoculation by introduction of foreign material laced with toxin) [3,15] which is likely to 196 
influence the antibody titre required for protection. The distance from the port of entry to 197 
the central nervous system (CNS) and the dose of toxin is likely to impact [15,16] as 198 
introduction of spores or toxin closer to the CNS may warrant higher IgG levels for protection 199 
than more peripheral injuries. In 104 reported equine cases of tetanus [14,17-19] none of the 200 
horses were known to have been completely vaccinated according to any of the current 201 
guidelines. There are cases with complete tetanus immunisations that have shown clinical 202 
signs of tetanus (Gaby van Galen, pers com 2014), but to the best of the authors´ knowledge, 203 
there are currently no reports of a horse with proven complete basic immunisation dying of 204 
or being euthanized due to severe tetanus.  205 
 206 
The fact that one horse had IgG levels below 0.04 IU/ml a year after complete basic 207 
immunisation may be of concern as it was not possible to distinguish if the horse was above 208 
the traditional cut-off of 0.01 IU/ml. This horse was excluded from the study and vaccinated 209 
at this time, and responded well with high serum titres found on testing the following year 210 
(5.84 IU/ml), data is not shown graphically or in the supplementary material as this horse was 211 
excluded from further analysis. It is unclear why this individual did not respond like the other 212 
horses. Several causes for failure are possible. Inherent individual low response is possible 213 
but unlikely in this case as the horse responded well to the first two vaccinations, and had a 214 
good response to the booster vaccination once removed from the study. Vaccine failure is 215 
possible due to incorrect storage or injection, however, other horses in this study were 216 
vaccinated at the same time and showed an appropriate IgG response. Some horses in the 217 
study showed an increase in anti-tetanus antibodies at time points when they had not 218 
received vaccinations. The reason for this is not known, but several mechanisms are possible. 219 
Firstly, this difference could be due to expected level of error for the serum ELISA. Variation 220 
in the method of analysis could account for some of the difference and ideally all the samples 221 
should have been analysed at the same time. However, this was not possible as the titres had 222 
to be assessed during the study in order to ensure that horses had acceptable levels of anti-223 
tetanus antibodies for protection. Acquired immunity is also possible as horses may have 224 
experienced subclinical infection with tetanus and a subsequent rise in titres. 225 
 226 
Although vaccinating often may pose little risk to the patient, veterinarians should strive to 227 
practice evidence based medicine. In countries where an annual vaccination against equine 228 
influenza is warranted, clients may elect to use a combination vaccine and thereby give a 229 
yearly booster of tetanus vaccine. However, in countries where influenza is not endemic, or 230 
in individuals that are not routinely vaccinated for reasons such as previous anaphylaxis, 231 
optimal recommendations for booster vaccination against tetanus is imperative. Tetanus is 232 
best prevented by prophylaxis, but the proposed titre limit of 0.01 IU/ml may be higher than 233 
needed for protection against disease. Current guidelines for tetanus vaccination are not 234 
based on sound scientific evidence and should be revised.  235 
 236 
Manufacturer’s details 237 
1Equilis Prequenza Te, Intervet AB, Stockholm, Sweden 238 
 239 
 240 
  241 
Table 1 242 
The number and percentage of horses remaining in the study at each time point. 243 
Variable Level Time 
point 0  
Number 
(%) 
n=34 
Time 
point 1  
Number 
(% 
remaining
) 
Time 
point 2 
Number 
(% 
remaining
) 
Time 
point 3 
Number 
(% 
remaining
) 
Time 
point 4  
Number 
(% 
remaining
) 
Time 
point 5  
Number 
(% 
remaining
) 
Age at 
start of 
study* 
5 months 2 (6) 2 (100) 2 (100) 1 (50) 2 (100) 1 (50) 
6 months 14 (41) 14 (100) 13 (93) 10 (71) 4 (29) 1 (7) 
7 months 6 (18) 6 (100) 5 (83) 5 (83) 5 (83) 2 (33) 
8 months 8 (24) 7 (88) 8 (100) 8 (100) 3 (38) 2 (25) 
 9 months 2 (6) 2 (100) 2 (100) 1 (50) 1 (50) 1 (50) 
 11 months 1 (3) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
        
Sex Colt 18 (53) 17 (94) 17 (94) 14 (78) 9 (50) 5 (28) 
 Filly 16 (47) 16 (100) 15 (94) 12 (75) 7 (44) 3 (19) 
        
Breed Connemara 4 (12) 4 (100) 4 (100) 3 (75) 2 (50) 2 (50) 
  Swedish 
Warmblood 
30 (88) 29 (97) 28 (93) 23 (77) 14 (47) 6 (20) 
*One horse with a missing value for age at the start of the study 244 
  245 
Figure legends 246 
Figure 1 247 
 248 
Median and IQR for anti-tetanus titres at the start of the study (time 0, n=20), two weeks after 249 
basic immunization with two doses of vaccine (time 1, n=34), 14-16 months after basic 250 
immunization (time 2, n=28), and yearly thereafter (time 3, n=25, time 4, n=16 and time 5, 251 
n=8). Horses with titres <0.04 were not included in the box plot. 252 
Time points for vaccinations in relation to testing are indicated as V1-V3. 253 
  254 
Figure 2 255 
 256 
Box plot showing horses with and without detectable (0.04 IU/ml) antibodies at the start of 257 
the study. The groups were only significantly different (P<0.01) at time point 1, i.e. 2 weeks 258 
after basic immunization.  259 
  260 
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